Related Experiment Video
Updated: Sep 27, 2025
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer
Amanda K Riley1,2, Alice H Berger1
1Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract:
In recent work, we performed CRISPR/Cas9 screening in RIT1 (Ras-like in all tissues)-mutant cancer cells. We found that RIT1-mutant cells are vulnerable to loss of mitotic regulators, and mutant RIT1 synergizes with YAP1 (yes-associated protein 1) in oncogenesis. These findings can be leveraged to identify targeted therapies for RIT1-mutant cancer.
Insights
Ras-like in all tissues (RIT1) mutations make cancer cells vulnerable to mitotic regulator loss. RIT1 mutations also synergize with yes-associated protein 1 (YAP1) in promoting cancer, suggesting new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ras-like in all tissues (RIT1) is a small GTPase involved in cell signaling.
- Mutations in RIT1 are found in various human cancers, but their functional consequences are not fully understood.
- Understanding RIT1's role in oncogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To identify vulnerabilities in RIT1-mutant cancer cells.
- To investigate the interaction between RIT1 and other oncogenic pathways, such as YAP1.
- To explore potential therapeutic strategies for RIT1-mutant cancers.
Main Methods:
- CRISPR/Cas9 screening was employed in RIT1-mutant cancer cell lines.
- Functional assays were performed to assess the impact of gene loss on cell viability.
- Genetic interaction analysis was conducted to study the synergy between RIT1 and YAP1.
Main Results:
- RIT1-mutant cancer cells exhibit synthetic lethality upon loss of specific mitotic regulators.
- Mutant RIT1 cooperates with yes-associated protein 1 (YAP1) to drive oncogenesis.
- The identified vulnerabilities provide a basis for targeted therapeutic interventions.
Conclusions:
- Loss of mitotic regulators represents a key vulnerability in RIT1-mutant cancers.
- The synergistic interaction between mutant RIT1 and YAP1 highlights a critical oncogenic pathway.
- Targeting these vulnerabilities could lead to effective treatments for patients with RIT1-mutant cancers.
